Eli Lilly is now selling Mounjaro GLP-1 weight loss drugs in India. Rival Novo Nordisk began Indian Wegovy sales in June.

The Q2 pharma earnings season featured changes in the obesity race as well as insights into drugmakers’ views on tariffs and drug pricing.

Lilly's Kwikpen debut intensifies rivalry with Novo Nordisk's Wegovy in the world's most populous diabetes market ...

Biogen CEO Chris Viehbacher says Novo Nordisk's Alzheimer's trial success could lead to combination therapies, boosting ...

NVO stock climbs nearly 6% in August as Lilly's oral obesity candidate setback pivots investor sentiment toward the former's ...

President Donald Trump has called on 17 pharmaceutical companies to implement most-favored-nation drug pricing in the next 60 days.

Eli Lilly on Wednesday launched the easy-to-use injector pen of its blockbuster weight-loss drug Mounjaro for 14,000 rupees ...

Response Pharmaceuticals has shared phase 2 data in post-GLP-1 patients, linking its ex-Sanofi asset to reductions in ...

Enthusiasm for its weight loss medications is intensifying, and several companies are preparing oral formulations.

(Reuters) -Doctors advise most patients on GLP-1 obesity drugs such as Wegovy and Zepbound to stay on them to keep the weight ...

(Reuters) -Eli Lilly launched the pre-filled injector pen of its blockbuster weight-loss drug Mounjaro for 14,000 rupees ...

Novo Nordisk has plummeted back to Earth after a stunning rise driven by Ozempic and Wegovy. Can the storied Danish pharma ...